Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: Analysis of the southwest oncology group database for antimicrotubule-platinum therapy

Karen Kelly, Kari Chansky, Philip Mack, Primo N Lara, Fred R. Hirsch, Wilbur A. Franklin, Antoinette J. Wozniak, Martin J. Edelman, Stephen K. Williamson, David R Gandara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective Histologic subtyping has been advocated to select chemotherapy for patients with advanced-stage non-small-cell lung cancer (NSCLC). To determine whether histologic subtype was associated with efficacy for the commonly used antimicrotubule (AMT) agents, paclitaxel, docetaxel, and vinorelbine plus a platinum compound, we examined the Southwest Oncology Group (SWOG) lung cancer database. Methods Data from 4 randomized trials (S9308, S9509, S9806, and S0003) administering an AMT agent plus platinum in patients receiving first-line treatment for advanced-stage NSCLC were analyzed. Overall survival (OS) and progression-free survival (PFS) comparisons were performed using Cox proportional hazard regression, adjusting for sex. Median survival times were estimated by Kaplan-Meier. Results Of 1146 patients included in this analysis, 640 had adenocarcinoma (56%), 220 had squamous cell carcinoma (19%), 121 had large cell carcinoma (11%), and 165 had NSCLC not otherwise specified (NOS) (14%). Median OS times by histologic subtypes were 8.5, 8.4, 8.2, and 9.6 months, respectively, and median PFS times were 4.2, 4.3, 4.3, and 4.6 months, respectively. No difference in OS or PFS was observed by histologic subtype and, specifically, between nonsquamous and squamous histologies. Conclusions This pooled analysis from 4 SWOG trials using an AMT-platinum regimen did not show a difference in survival outcomes by histologic subtype. Because the majority of patients with advanced NSCLC continue to receive chemotherapy, defining molecular-based predictive markers of responsiveness is warranted.

Original languageEnglish (US)
Pages (from-to)627-635
Number of pages9
JournalClinical Lung Cancer
Volume14
Issue number6
DOIs
StatePublished - Nov 2013

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Databases
Drug Therapy
Survival
Disease-Free Survival
docetaxel
Platinum Compounds
Therapeutics
Large Cell Carcinoma
Paclitaxel
Squamous Cell Carcinoma
Lung Neoplasms
Histology
Adenocarcinoma

Keywords

  • Chemotherapy outcomes
  • Histology
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer : Analysis of the southwest oncology group database for antimicrotubule-platinum therapy. / Kelly, Karen; Chansky, Kari; Mack, Philip; Lara, Primo N; Hirsch, Fred R.; Franklin, Wilbur A.; Wozniak, Antoinette J.; Edelman, Martin J.; Williamson, Stephen K.; Gandara, David R.

In: Clinical Lung Cancer, Vol. 14, No. 6, 11.2013, p. 627-635.

Research output: Contribution to journalArticle

Kelly, Karen ; Chansky, Kari ; Mack, Philip ; Lara, Primo N ; Hirsch, Fred R. ; Franklin, Wilbur A. ; Wozniak, Antoinette J. ; Edelman, Martin J. ; Williamson, Stephen K. ; Gandara, David R. / Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer : Analysis of the southwest oncology group database for antimicrotubule-platinum therapy. In: Clinical Lung Cancer. 2013 ; Vol. 14, No. 6. pp. 627-635.
@article{43097c7653964bfeae64d26fd5a57aca,
title = "Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: Analysis of the southwest oncology group database for antimicrotubule-platinum therapy",
abstract = "Objective Histologic subtyping has been advocated to select chemotherapy for patients with advanced-stage non-small-cell lung cancer (NSCLC). To determine whether histologic subtype was associated with efficacy for the commonly used antimicrotubule (AMT) agents, paclitaxel, docetaxel, and vinorelbine plus a platinum compound, we examined the Southwest Oncology Group (SWOG) lung cancer database. Methods Data from 4 randomized trials (S9308, S9509, S9806, and S0003) administering an AMT agent plus platinum in patients receiving first-line treatment for advanced-stage NSCLC were analyzed. Overall survival (OS) and progression-free survival (PFS) comparisons were performed using Cox proportional hazard regression, adjusting for sex. Median survival times were estimated by Kaplan-Meier. Results Of 1146 patients included in this analysis, 640 had adenocarcinoma (56{\%}), 220 had squamous cell carcinoma (19{\%}), 121 had large cell carcinoma (11{\%}), and 165 had NSCLC not otherwise specified (NOS) (14{\%}). Median OS times by histologic subtypes were 8.5, 8.4, 8.2, and 9.6 months, respectively, and median PFS times were 4.2, 4.3, 4.3, and 4.6 months, respectively. No difference in OS or PFS was observed by histologic subtype and, specifically, between nonsquamous and squamous histologies. Conclusions This pooled analysis from 4 SWOG trials using an AMT-platinum regimen did not show a difference in survival outcomes by histologic subtype. Because the majority of patients with advanced NSCLC continue to receive chemotherapy, defining molecular-based predictive markers of responsiveness is warranted.",
keywords = "Chemotherapy outcomes, Histology, Lung cancer",
author = "Karen Kelly and Kari Chansky and Philip Mack and Lara, {Primo N} and Hirsch, {Fred R.} and Franklin, {Wilbur A.} and Wozniak, {Antoinette J.} and Edelman, {Martin J.} and Williamson, {Stephen K.} and Gandara, {David R}",
year = "2013",
month = "11",
doi = "10.1016/j.cllc.2013.06.010",
language = "English (US)",
volume = "14",
pages = "627--635",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer

T2 - Analysis of the southwest oncology group database for antimicrotubule-platinum therapy

AU - Kelly, Karen

AU - Chansky, Kari

AU - Mack, Philip

AU - Lara, Primo N

AU - Hirsch, Fred R.

AU - Franklin, Wilbur A.

AU - Wozniak, Antoinette J.

AU - Edelman, Martin J.

AU - Williamson, Stephen K.

AU - Gandara, David R

PY - 2013/11

Y1 - 2013/11

N2 - Objective Histologic subtyping has been advocated to select chemotherapy for patients with advanced-stage non-small-cell lung cancer (NSCLC). To determine whether histologic subtype was associated with efficacy for the commonly used antimicrotubule (AMT) agents, paclitaxel, docetaxel, and vinorelbine plus a platinum compound, we examined the Southwest Oncology Group (SWOG) lung cancer database. Methods Data from 4 randomized trials (S9308, S9509, S9806, and S0003) administering an AMT agent plus platinum in patients receiving first-line treatment for advanced-stage NSCLC were analyzed. Overall survival (OS) and progression-free survival (PFS) comparisons were performed using Cox proportional hazard regression, adjusting for sex. Median survival times were estimated by Kaplan-Meier. Results Of 1146 patients included in this analysis, 640 had adenocarcinoma (56%), 220 had squamous cell carcinoma (19%), 121 had large cell carcinoma (11%), and 165 had NSCLC not otherwise specified (NOS) (14%). Median OS times by histologic subtypes were 8.5, 8.4, 8.2, and 9.6 months, respectively, and median PFS times were 4.2, 4.3, 4.3, and 4.6 months, respectively. No difference in OS or PFS was observed by histologic subtype and, specifically, between nonsquamous and squamous histologies. Conclusions This pooled analysis from 4 SWOG trials using an AMT-platinum regimen did not show a difference in survival outcomes by histologic subtype. Because the majority of patients with advanced NSCLC continue to receive chemotherapy, defining molecular-based predictive markers of responsiveness is warranted.

AB - Objective Histologic subtyping has been advocated to select chemotherapy for patients with advanced-stage non-small-cell lung cancer (NSCLC). To determine whether histologic subtype was associated with efficacy for the commonly used antimicrotubule (AMT) agents, paclitaxel, docetaxel, and vinorelbine plus a platinum compound, we examined the Southwest Oncology Group (SWOG) lung cancer database. Methods Data from 4 randomized trials (S9308, S9509, S9806, and S0003) administering an AMT agent plus platinum in patients receiving first-line treatment for advanced-stage NSCLC were analyzed. Overall survival (OS) and progression-free survival (PFS) comparisons were performed using Cox proportional hazard regression, adjusting for sex. Median survival times were estimated by Kaplan-Meier. Results Of 1146 patients included in this analysis, 640 had adenocarcinoma (56%), 220 had squamous cell carcinoma (19%), 121 had large cell carcinoma (11%), and 165 had NSCLC not otherwise specified (NOS) (14%). Median OS times by histologic subtypes were 8.5, 8.4, 8.2, and 9.6 months, respectively, and median PFS times were 4.2, 4.3, 4.3, and 4.6 months, respectively. No difference in OS or PFS was observed by histologic subtype and, specifically, between nonsquamous and squamous histologies. Conclusions This pooled analysis from 4 SWOG trials using an AMT-platinum regimen did not show a difference in survival outcomes by histologic subtype. Because the majority of patients with advanced NSCLC continue to receive chemotherapy, defining molecular-based predictive markers of responsiveness is warranted.

KW - Chemotherapy outcomes

KW - Histology

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84887224108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887224108&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2013.06.010

DO - 10.1016/j.cllc.2013.06.010

M3 - Article

C2 - 23910067

AN - SCOPUS:84887224108

VL - 14

SP - 627

EP - 635

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -